Wedbush Maintained an Underperform Rating on Praxis Precision Medicines, Inc. (PRAX)

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is one of the 10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen.

On May 8, TheFly reported that a Wedbush analyst bumped up Praxis Precision Medicines, Inc. (NASDAQ:PRAX)’s price target from $130 to $166. It maintained an “Underperform” rating and flagged concerns about the ulixacaltamide filing and valuation.

On May 7, Praxis Precision Medicines, Inc. (NASDAQ:PRAX) stated that the FDA has accepted NDAs for ulixacaltamide and relutrigine, with PDUFA dates of January 29, 2027, and September 27, 2026. CEO Marcio Souza said that the company is “positioning us for two U.S. launches within the next eight months,” given EMBRAVE research showing a 77% reduction in placebo-adjusted seizure rates.

Wedbush Maintained an Underperform Rating on Praxis Precision Medicines, Inc. (PRAX)

The company ended the quarter with cash and investments of about $1.4 billion as of March 31, 2026, extending its runway into 2028. It posted a net loss of $92.6 million for the quarter. The firm’s research and development spending went to $78.0 million, while general and administrative costs reached $27.9 million.

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) also stated that it expects extra clinical readouts in 2026. This includes the POWER1 and EMERALD trials.

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is a clinical-stage biopharmaceutical company. It works on two proprietary platforms, i.e., Cerebrum and Solidus.

While we acknowledge the risk and potential of PRAX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PRAX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.